🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to researchers.

An International Challenge

Cases of gonorrhoea are increasing worldwide, with figures suggesting in excess of 82 million infections each year. Especially elevated rates are observed in Africa and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely development in the context of rising global incidence, the spread of superbugs and the very limited therapeutic options at this time.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring showed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts believe that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This drug, which is additionally indicated for UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This milestone represents a major breakthrough in the therapy of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Research Study Results and Worldwide Availability

Based on findings detailed in a prominent scientific publication, zoliflodacin cured over nine in ten of cases of the STI. This establishes an equal footing with the current standard treatment, which uses two antibiotics. The research enrolled hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the ability to register and commercialise the drug in numerous regions with limited resources.

Doctors on the front lines have shared hope. Access to a one-pill regimen like this is seen as a "revolutionary step" for gonorrhoea control. This is viewed as vital to alleviate the strain of the illness for people and to prevent the spread of extremely resistant gonorrhoea globally.